Thursday, July 18, 2024 Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a prominent innovation-driven biopharmaceutical company, has announced that the National Medical Products Administration (NMPA) has accepted for review the supplemental new drug application (sNDA) for toripalimab (trade name: TUOYI®, product code: JS001) in combination with bevacizumab for the first-line treatment of unresectable or metastatic hepatocellular carcinoma (HCC). Liver cancer, particularly hepatocellular carcinoma (HCC), is a major malignant tumor affecting the digestive system worldwide, accounting for approximately 90% of cases.
The 2022 GLOBOCAN Report documented 866,000 new liver cancer cases and 759,000 deaths globally, with China bearing a significant burden of this disease. In 2022, China reported 368,000 new liver cancer cases, representing 42.4% of the global incidence, and 317,000 deaths, accounting for 41.
7% of global liver cancer fatalities. Liver cancer ranks fourth in new cases and second in deaths among domestic malignancies in China. Due to its asymptomatic nature, 70%-80% of liver cancer patients in China are diagnosed at intermediate or advanced stages, with a median overall survival (OS) of about 10 months and a 5-year survival rate of approximately 12%.
Recent advancements in combination therapies involving immunotherapy drugs have revolutionized the treatment landscape for advanced liver cancer, making radical cures more achievable. The.